SCHEMBL1323237

SCHEMBL1323237

COc1ccc(CCOC(=N)C(Cl)(Cl)Cl)cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.49
ATM Q13315 2/20 0.49
KDM4E B2RXH2 1/20 0.49
KMT2A Q03164 2/20 0.48
STAT3 P40763 1/20 0.47
POLB P06746 1/20 0.46
CYP19A1 P11511 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CA2 P00918 2/20 0.46
APP P05067 1/20 0.45
BLM P54132 1/20 0.45
PMP22 Q01453 1/20 0.45
AOC3 Q16853 1/20 0.44
ALDH1A1 P00352 1/20 0.44
PPARG P37231 1/20 0.44
PPARD Q03181 1/20 0.44
PPARA Q07869 1/20 0.44
MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12296002 0.93 MAPT (0.44) MAPTATMKDM4EKMT2ASTAT3
SCHEMBL12295983 0.93 MAPT (0.44) MAPTATMKDM4EKMT2ASTAT3
SCHEMBL12296014 0.90 MAPT (0.40) MAPTATMKDM4EKMT2ASTAT3
SCHEMBL2632620 0.89 CHRM5 (0.42) MAPTATMKDM4EKMT2ACYP1A2
SCHEMBL16481554 0.89 CYP1A2 (0.54) KMT2ACYP19A1CYP1A2CYP3A4APP
SCHEMBL2632438 0.89 MET (0.38) MAPTATMKDM4EKMT2ASTAT3
SCHEMBL12328264 0.88 SIGMAR1 (0.46)
SCHEMBL12327945 0.88 HDAC1 (0.45) KMT2AALDH1A1MEN1
SCHEMBL12296056 0.86 BCHE (0.50) KDM4EKMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL12296038 0.86 KDM4E (0.52) KDM4EKMT2ACYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110105245-A A kind of preparation method of Vernakalant intermediate 3,4- Dimethoxyphenethyl 2,2,2- tribromo-acetyl imines 北京哈三联科技有限责任公司 2019-08-09 CN disclosed
CN-105294530-B A kind of process for purification of Vernakalant hydrochloride 北京哈三联科技有限责任公司 2018-01-23 CN disclosed
CN-104610121-B A kind of preparation method of Vernakalant hydrochloride 北京哈三联科技有限责任公司 2017-11-07 CN disclosed
US-9586899-B2 Synthetic process for aminocyclohexyl ether compounds CARDIOME PHARMA CORP. (CA) 2017-03-07 US disclosed
US-9586899-B2 Synthetic process for aminocyclohexyl ether compounds CARDIOME PHARMA CORP. (CA) 2017-03-07 US disclosed
CN-105294530-A Purification method of vernakalant hydrochloride MEDISANTECH CORP 2016-02-03 CN disclosed
US-20150336887-A1 SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS CORREVIO CANADA CORP. (CA) 2015-11-26 US disclosed
US-20150336887-A1 SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS CORREVIO CANADA CORP. (CA) 2015-11-26 US disclosed
US-9115081-B2 Synthetic process for aminocyclohexyl ether compounds CARDIOME PHARMA CORP. (CA) 2015-08-25 US disclosed
US-9115081-B2 Synthetic process for aminocyclohexyl ether compounds CARDIOME PHARMA CORP. (CA) 2015-08-25 US disclosed
US-20080021005-A1 Pegylated Ion Channel Modulating Compounds CARDIOME PHARMA CORP. (CA) 2008-01-24 US disclosed
US-20070254945-A1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2007-11-01 US disclosed
US-20070099983-A1 Aminocyclohexyl ether compounds and uses thereof CARDIOME PHARMA CORP. (CA) 2007-05-03 US disclosed
US-20070088075-A1 Deuterated aminocyclohexyl ether compounds and processes for preparing same CARDIOME PHARMA CORP. (CA) 2007-04-19 US disclosed
US-20070088075-A1 Deuterated aminocyclohexyl ether compounds and processes for preparing same CARDIOME PHARMA CORP. (CA) 2007-04-19 US disclosed
US-20070015924-A1 Synthetic processes for the preparation of aminocyclohexyl ether compounds CARDIOME PHARMA CORP. (CA) 2007-01-18 US disclosed
US-20060094880-A9 Synthetic process for trans-aminocyclohexyl ether compounds BARRETT ANTHONY G M 2006-05-04 US disclosed
WO-2005097087-A2 MERGED ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2005-10-20 WO disclosed
WO-2005016242-A2 SYNTHETIC PROCESS FOR TRANS-AMINOCYCLOHEXYL ETHER COMPOUNDS CARDIOME PHARMA CORP. (CA) 2005-02-24 WO disclosed
US-20050038256-A1 Synthetic process for trans-aminocyclohexyl ether compounds CARDIOME PHARMA CORP. (CA) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094880-A9 Synthetic process for trans-aminocyclohexyl ether compounds AKR1C3, CBR1, CBR3 MAPT 4883/4885ATM 2750/4885KDM4E 3727/4885
US-20080021005-A1 Pegylated Ion Channel Modulating Compounds KCNN3, KCNN2, KCNN1 MAPT 1655/4885ATM 4463/4885KDM4E 3982/4885
US-20070088075-A1 Deuterated aminocyclohexyl ether compounds and processes for preparing same DDC, HDHD5, DDT MAPT 3508/4885ATM 2258/4885KDM4E 265/4885
US-20070254945-A1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF KCNH2, KCNC1, KCNH3 MAPT 4479/4885ATM 3572/4885KDM4E 403/4885
US-20050038256-A1 Synthetic process for trans-aminocyclohexyl ether compounds AKR1C3, CBR1, CBR3 MAPT 4883/4885ATM 2750/4885KDM4E 3727/4885
US-20150336887-A1 SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS DDC, PAICS, CYP4F2 MAPT 3088/4885ATM 1974/4885KDM4E 1008/4885
US-20070015924-A1 Synthetic processes for the preparation of aminocyclohexyl ether compounds CYP2D6, CYP3A43, CYP2F1 MAPT 3487/4885ATM 3961/4885KDM4E 963/4885
US-20070099983-A1 Aminocyclohexyl ether compounds and uses thereof KCNH2, KCNC1, KCNH3 MAPT 4479/4885ATM 3572/4885KDM4E 403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.